Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer

• Published in: Breast cancer research and treatment 2017-05, Vol.163 (1), p.103-110
• Main Authors: Zetterlund, Linda Holmstrand, Frisell, Jan, Zouzos, Athanasios, Axelsson, Rimma, Hatschek, Thomas, de Boniface, Jana, Celebioglu, Fuat
• Format: Article
• Language: English
• Subjects: Adjuvant chemotherapy; Adult; Aged; Aged, 80 and over; Anthracyclines - therapeutic use; Aromatase Inhibitors - therapeutic use; Axilla; Biopsy; Breast cancer; Breast Neoplasms - therapy; Cancer research; Cancer therapies; Clinical Trial; Clinical trials; Female; Hospitals; Humans; Lymph node biopsy; Lymph Node Excision - methods; Lymphatic Metastasis; Lymphatic system; Mastectomy - methods; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy; Oncology; Prospective Studies; Sensitivity and Specificity; Sentinel Lymph Node Biopsy - methods; Sweden; Taxoids - therapeutic use
• ISSN: 0167-6806; 1573-7217; 1573-7217
• DOI: 10.1007/s10549-017-4164-1

Purpose Patients with clinically node-positive breast cancer planned for neoadjuvant systemic therapy (NAST) may draw advantages from the nodal downstaging effect and reduce the extent of axillary surgery with sentinel lymph node biopsy (SLNB) performed after NAST. Since there are concerns about lower sentinel lymph node (SLN) detection and higher false-negative rates (FNR) in this setting, our aim was to define the accuracy of SLNB after NAST. Methods This Swedish national multicenter trial prospectively recruited 195 breast cancer patients from ten hospitals with T1–T4d biopsy-proven node-positive disease planned for NAST between October 1, 2010 and December 31, 2015. Clinically node-negative axillary status after NAST was not mandatory. SLNB was always attempted and followed by a completion axillary lymph node dissection (ALND). Results The SLN identification rate was 77.9% (152/195) but improved to 80.7% (138/171) with dual mapping. The median number of SLNs was two (range 1–5). A positive SLNB was found in 52% (79/152), almost 66% (52/79) of whom had additional positive non-sentinel lymph nodes. The overall pathologic nodal response rate was 33.3% (66/195). The overall FNR was 14.1% (13/92) but decreased to 4% (2/50) when only patients with two or more sentinel nodes were analyzed. Conclusions In biopsy-proven node-positive breast cancer, SLNB after NAST is feasible even though the identification rate is lower than in clinically node-negative patients. Since the overall FNR is unacceptably high, the omission of ALND should only be considered if two or more SLNs are identified.